← Leaderboards
Fiona Simpkins
University Of Pennsylvania
$7,878,903
Attributed
$9,894,644
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,894,644 · 7
By mechanism
R37$2,606,732 · 1
P50$2,357,300 · 2
R44$1,996,571 · 1
R01$1,369,387 · 1
K08$807,480 · 1
U54$757,174 · 1
Top collaborators
- Eric J Brown4 shared
- Oren Gilad2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Eric J Brown$8,645,404
- Yongwon Choi$29,322,504
- Joel S. Bennett$17,907,964
- Haineng Xu$224,104
- Omaida C Velazquez$7,997,904
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryTumorResponseResistanceClinicFutureClinical TrialsCancer PatientRecurrenceMalignant NeoplasmsPhosphotransferasesGenomicsOverexpressionCancer CellSerousCombined Modality TherapyPre-ClinicalMolecularPredictive MarkerChemotherapyPlatinumMutationPreventNovel Therapeutics
Grant awards (27)
Developing biomarkers of response for a new therapy in ovarian cancer$676,860
R01 · FY2025 · CA · contact PI
Project 2: Targeting CCNE1 overexpression in high grade serous ovarian cancer$300,358
P50 · FY2025 · CA · contact PI
Platform to develop targeted therapies for aggressive less common gynecological cancers$256,669
U54 · FY2025 · CA · contact PI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$1,134,366
R44 · FY2024 · CA
Developing biomarkers of response for a new therapy in ovarian cancer$692,527
R01 · FY2024 · CA · contact PI
Project 2: Targeting CCNE1 overexpression in high grade serous ovarian cancer$514,106
P50 · FY2024 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$378,217
R37 · FY2024 · CA · contact PI
Platform to develop targeted therapies for aggressive less common gynecological cancers$243,836
U54 · FY2024 · CA · contact PI
Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer$862,205
R44 · FY2023 · CA
A novel more effective genotoxic therapy for ovarian cancer$398,125
R37 · FY2023 · CA · contact PI
Platform to develop targeted therapies for aggressive less common gynecological cancers$256,669
U54 · FY2023 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$368,288
R37 · FY2022 · CA · contact PI
"Optimizing synthetic lethality in high-grade serous ovarian cancer"$301,950
P50 · FY2022 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$368,288
R37 · FY2021 · CA · contact PI
"Optimizing synthetic lethality in high-grade serous ovarian cancer"$256,092
P50 · FY2021 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$368,288
R37 · FY2020 · CA · contact PI
"Optimizing synthetic lethality in high-grade serous ovarian cancer"$261,716
P50 · FY2020 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$357,238
R37 · FY2019 · CA · contact PI
"Optimizing synthetic lethality in high-grade serous ovarian cancer"$348,426
P50 · FY2019 · CA · contact PI
"Optimizing synthetic lethality in high-grade serous ovarian cancer"$374,652
P50 · FY2018 · CA · contact PI
A novel more effective genotoxic therapy for ovarian cancer$368,288
R37 · FY2018 · CA · contact PI
Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$130,770
K08 · FY2016 · CA · contact PI
Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$30,798
K08 · FY2015 · CA · contact PI
Targeting SRC Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$161,528
K08 · FY2014 · CA · contact PI
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$161,488
K08 · FY2013 · CA · contact PI
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$161,488
K08 · FY2012 · CA · contact PI
Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer$161,408
K08 · FY2011 · CA · contact PI